跳到正文
原文
STAT 主站· Damian Garde·· 4 天前AI 评分48

BeOne和恒瑞医药位列中国最具影响力的生物医药公司前两名

BeOne, Hengrui top list of China’s most powerful drugmakers

AI 导读

文章列出中国最具影响力的25家生物医药公司,BeOne和恒瑞医药分别排名第一和第二。文章反映了中国生物医药产业的崛起和国际竞争态势。

正文

By Damian Garde

Nov. 16, 2026

Reporter at Large, Live and Feature Journalism

China’s ascendant drug industry is no monolith, despite how it’s often described by Western competitors, pundits, and policymakers. The country is home to scores of companies with diverging ambitions, founded last year or last century, each vying for attention and capital amid a domestic scientific renaissance and a geopolitical standoff. 

It’s complicated. To help make sense of it, STAT and the risk intelligence platform WireScreen on Monday published China’s Biotech Powerhouse 25, a ranking of the country’s most valuable publicly traded firms that tracks the varying strategies — and fortunes — of the world’s rapidly growing new medicine chest.

The list’s top-ranked firms typify China’s rise to prominence on the global stage and the forking paths to get there. 

At No. 1 is BeOne Medicines, formerly known as BeiGene, a company founded in 2010 to straddle East and West that has become one of the first Chinese firms to build a worldwide sales operation. In second place is Jiangsu Hengrui Pharmaceuticals, which began nearly 60 years ago as a state-owned generics firm and has evolved into the partner of choice for Western pharma giants looking to in-license promising new medicines. One company seized on the need for new cancer medicines to establish a commercial beachhead in the U.S.; the other has capitalized on the gold rush for potential blockbusters developed swiftly and efficiently. Each is worth nearly $50 billion as a result.

The rankings — and attendant scores given to each company — are based on two equally weighted metrics: market value and revenue. Companies are put on a scale of 0 to 50 compared to the leader on each of the two measures, meaning a company leading both would get 100. Only Chinese firms whose primary business is discovering novel medicines for human disease were eligible, meaning the list includes no contract research firms, pharmaceutical service providers, or generics companies. 

STAT and WireScreen plan to update the rankings each quarter as licensing deals, product launches, and market forces affect the fortunes of the country’s emerging powerbrokers.

Beijing has made biopharma a national priority, aiming to produce at least a quarter of the world’s first-in-class drugs by 2030 and host at least 50 domestic companies worth $1 billion or more. Washington and even the biotech industry itself are hung up over how to respond, caught between an impulse to demand what would amount to molecular import controls and pharmaceutical companies that want to keep shopping for low-cost intellectual property from Chinese labs.

Last month, the Trump administration moved to block certain deals between U.S. firms and Chinese drugmakers, proposing controversial changes to a law called COINS, short for the Comprehensive Outbound Investment National Security Act. Given President Trump’s unpredictability and the political shift in Washington set to take place following the midterm elections, no one’s certain of how the policy landscape might be affected. 

“The relationship between nations is pretty dynamic, where Trump can have a productive meeting with President Xi and then turn around and put out a rule on COINS,” said Leonid Timashev, an analyst at RBC Capital Markets who covers biotech.

Many in the U.S. drug industry are advocating for policies aimed at accelerating domestic drug development, not curtailing progress in China. John Crowley, president and CEO of the Biotechnology Innovation Organization, sees China’s biopharmaceutical ascension as grounds for a modern-day Space Race, one that demands the U.S. bolster its research spending, speed up the process of running clinical trials, and incentivize companies to make their drugs in America. 

“The next century of biotechnology leadership is not destined to belong to any nation,” Crowley wrote in STAT. “It will be earned by the nation with the vision to invest, the courage to innovate, and the resolve to build the future.”

By most metrics — number of clinical trials, research spending, patents filed — that nation is China. But, as each update of the Powerhouse 25 is likely to illustrate, the Chinese biotech industry only prospers if all that work turns into drugs that work in the clinic and sell on the market.

来源:STAT 主站 · statnews.com